Publicaciones | REFINE

Sullivan FM et al. Early Diagnosis of Lung Cancer Scotland (ECLS) Team. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur Respir J. 2020,30:2000670.

Tanner NT et al. Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons. Clin Lung Cancer. 2020;21:e89-e98.

Jett J. et al. Potential utility of a positive EarlyCDT®-Lung blood biomarker test in indeterminate pulmonary nodules. Journal of Thoracic Oncology, 2018; 13:10S.

Edelsberg J. et al. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules. PLoS One. 2018; 13:e0197826.

Jett J. et al. Determination of the Detection Lead Time for Autoantibody Biomarkers in Early Stage Lung Cancer Using the UKCTOCS Cohort. Journal of Thoracic Oncology, 12:11S2

Healey GF et al. Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT®-Lung Diagnostic Performance and its Application to Indeterminate Pulmonary Nodules. J Cancer Ther. 2017; 8:506-517.

Massion PP et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol. 2017; 12:578-584.

Sullivan FM et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer. 2017; 17:187.

Macdonald IK et al. Autoantibodies:Opportunities for Early Cancer Detection. Trends Cancer. 2017; 3:198-213.

Jett JR et al. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014; 83:51-5.

Healey GF et al. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis. 2013; 5:618-25.

Macdonald IK et al. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test. PLoS One. 2012; 7:e51002.

Chapman CJ et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33:1319-26.

Macdonald IK et al. Development and validation of a high throughput system for discovery of antigens for autoantibody detection. PLoS One. 2012; 7:e40759.

Lam S et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011; 4:1126-34.

Chapman CJ et al. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res. 2011; 17:1474-80.

Boyle P et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011; 22:383-9.

Murray A et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol. 2010; 21:1687-1693.